Effectiveness of Midazolam for Seizure Cluster Management: Kamil Detyniecki, MD
November 21st 2023The associate professor of clinical neurology at the University of Miami Miller School of Medicine talked about findings from a recent post hoc analysis assessing the FDA-approved treatment of midazolam for seizure clusters. [WATCH TIME: 3 minutes]
Intermittent Use of Midazolam Shows Continued Favorable Profile in Seizure Clusters
November 16th 2023In a recent post hoc analysis, findings showed that nearly 50% of patients treated with 1 or 2 doses of midazolam experienced return to full baseline functionality in 1 hour of administration.
The Potential of Genetic Therapies in Neuromuscular Diseases: Stephan Züchner, MD, PhD
April 4th 2023At the 2023 MDA conference, the professor for human genetics and neurology at the University of Miami Miller School of Medicine talked about the role of genetics in neuromuscular diseases and potential therapies. [WATCH TIME: 5 minutes]
Improving Biomarker Selection and Treating the Underlying Pathology of Dementia With Lewy Bodies
December 19th 2022James Galvin, MD, MPH, director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine, provided insight on the unmet needs for dementia with Lewy bodies, and whether success in Alzheimer disease can help.
Expanding the Pathways to Treat Dementia With Lewy Bodies: James Galvin, MD, MPH
December 7th 2022The director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine detailed the need for improved biomarkers of dementia with Lewy bodies and whether research in Alzheimer disease helps propel the field. [WATCH TIME: 3 minutes]
Addressing Unmet Needs of Dementia With Lewy Bodies: James Galvin, MD, MPH
December 2nd 2022The director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine discussed the treatment differences and unmet needs between dementia with Lewy bodies and Alzheimer disease. [WATCH TIME: 4 minutes]
Role of the Cognitive Stress Test in Improving Future Alzheimer Clinical Trials: Rosie Curiel, PsyD
September 1st 2022The associate professor of neuropsychology at the University of Miami Miller School of Medicine discussed how a new innovative tool can further characterize cognitive status and improve evaluation of agents in development for Alzheimer disease. [WATCH TIME: 2 minutes]
Expanding on the Cognitive Stress Test and Answering Cognitive Deficit Questions: Rosie Curiel, PsyD
August 25th 2022The associate professor of neuropsychology at the University of Miami Miller School of Medicine discussed the next steps in using the Cognitive Stress Test and the remaining questions from recent findings. [WATCH TIME: 4 minutes]
Using the Cognitive Stress Test to Distinguish Pre-MCI and Amnestic MCI: Leeron Nahmias, BS
August 9th 2022The medical student at Nova Southeastern University provided insight on a new innovative tool called the Cognitive Stress Test that can help distinguish different cognitive states for older adults. [WATCH TIME: 6 minutes]
Tackling the Global Issue of Ancestral Disparities in Alzheimer Disease: Margaret Pericak-Vance, PhD
July 21st 2022The director of the John P. Hussman Institute for Human Genomics at the University of Miami discussed the background behind a new initiative geared towards understanding genetic differences of underrepresented groups. [WATCH TIME: 6 minutes]
Dosing Commences in Phase 2 Study of CT1812 in Dementia With Lewy Bodies
July 18th 2022The double-blind, placebo-controlled, randomized trial will evaluate CT1812, a small molecule therapeutic designed to address the dual assault from α-synuclein and amyloid-ß oligomers in patients with dementia with Lewy bodies.
Expanding Genetic Associations Between Races and Alzheimer Disease: Margaret Pericak-Vance, PhD
July 18th 2022The director of the John P. Hussman Institute for Human Genomics at the University of Miami discussed non-APOE–related genetic correlations between different groups of individuals and Alzheimer disease. [WATCH TIME: 5 minutes]
The Role of Genetics in Alzheimer Drug Development: Margaret Pericak-Vance, PhD
July 15th 2022The director of the John P. Hussman Institute for Human Genomics at the University of Miami provided insight on the outlook on genetics and gene-based therapies for Alzheimer disease. [WATCH TIME: 3 minutes]
Neflamapimod Displays Robust Efficacy in Pure Lewy Body Dementia Pathology
November 19th 2021The magnitude of neflamapimod’s effect on several efficacy measures proved to be consistent with the mechanism of action and prior preclinical data, with p-tau181 data suggesting a stronger effect on nonmixed Lewy body pathology.
COVID-19’s Potential Effect on Dementia Risk: James E. Galvin, MD, MPH
September 1st 2021The director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine discussed the current understanding of COVID-19 and its associations with cognitive decline and Alzheimer disease.
Dementia Research in Multicultural Communities: James E. Galvin, MD, MPH
August 30th 2021The director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine discussed projects dedicated towards improving dementia recognition and care within multicultural communities.
NeuroVoices: James Galvin, MD, MPH, on Location and Greenhouse Space Effects on Alzheimer Risk
August 18th 2021The director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine provided context on greenhouse spaces and their preventive benefits in Alzheimer disease.
Associations Between Greenspace and Cognitive Performance: James E. Galvin, MD, MPH
August 16th 2021The director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine discussed the clinical significance of his findings on neighborhood tree canopy and brain health.